The University of Tokyo Hospital has begun a specific clinical study in which the acute pancreatitis drug "Fusan" and the new influenza drug "Abigan" are used in combination for patients who have developed pneumonia after being infected with the new coronavirus.Expectations are likely to rise toward the establishment of a cure for the new corona infection.
According to the University of Tokyo, the patients with new corona infection to be studied are those aged 20 to 74 years with pneumonia, including the University of Tokyo Hospital, the National Mutual Aid Association Toranomon Hospital in Tokyo, and the Tokyo Medical and Dental University Hospital6. Start clinical research at the facility and add participating facilities one by one.
In addition to the research results that Fusan has the potential to prevent the new corona from invading human cells, the Institute of Medical Science of the University of Tokyo has the effect of preventing blood from clotting, and the new corona is severely ill. It is also expected to prevent the onset of thrombi, which is common in many cases.Avigan is underway in several specific clinical studies as a potential candidate for a new corona treatment that prevents the replication of viral genes in cells.
The researchers believe that Fusan and Avigan work differently in the virus's growth process, so their combined use will increase their effectiveness.For this reason, patients will be divided into a group receiving both Fusan and Avigan and a group receiving only Avigan, and the efficacy and safety will be compared after administration for up to 2 weeks.
Fusan will be provided free of charge by Nichi-Iko and Avigan will be provided free of charge by Fuji Film Toyama Chemical, and safety information on each drug will be provided.
